［1］Pavel Nemec，Zuzana Zemanova.Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy［J］.Biology of Blood and Marrow Transplantation，2010，16(4)：548-554.
［2］Zhang ZN.Blood disease diagnosis and treatment standards［M］.Beijing:Science Press，2007：232-235.［张之南.血液病诊断及疗效标准［M］.北京：科学出版社，2007：232-235.］
［3］Deng SH.Features of extramedullary disease of multiple myeloma：high frequency of p53 deletion and poor survival：a retrospective single-center study of 834 cases［J］.Clinical Lymphoma Myeloma and Leukemia，2015，15(5)：286-291.
［4］Chng WJ，Price-Troska T，Gonzalez-Paz，et al.Clinical significance of TP53 mutation in myeloma［J］.Leukemia，2007，21：582-584.
［5］Fonseca R，Barlogie B，Bataille R，et al.Genetics and cytogenetics of multiple myeloma：A workshop report［J］.Cancer Res，2004，64：1546-1558.
［6］Segges P，Braggio E，Minnicelli C，et al.Genetic aberrations in multiple myeloma characterized by cIg-FISH：a Brazilian context［J］.Brazilian J Medical and Biological Res，2016，49(5)：e5034.
［7］Chim CS，Sim J，Tam S，et al.LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens［J］.Eur J Haematol，2015，94(4)：330-335.
［8］KD Boyd，FM Ross，WJ Tapper，et al.The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy［J］.Genes Chromosomes and Cancer，2011，50：765-774.
［9］Moreau P，Cavo M，Sonneveld P，et al.The combination of ISS3，high LDH and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-lineautologous stem cell transplantation at high-risk of early MM progression-related death［J］.J Clin Oncol，2014，132(20)：2173-2180.
［10］Hebraud B，Magrangeas F，Cleynen A，et al.Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma：the IFM experience［J］.Blood，2015，125(13)：2095-2100.
［11］S Mangiacavalli，L Pochintesta，F Cocito，et al.Correlation between burden of 17p13.1 alteration and rapid escape toplasma cell leukaemia in multiple myeloma［J］.British J Haematol，2013，162：555-558.
［12］Reece D，Song KW，Fu T，et al.Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone：Adverse effect of deletion 17p13［J］.Blood，2009，114：522-525.
［13］Sonneveld P，Avet-Loiseau H，Lonial S，et al.Treatment of multiple myeloma with high-risk cytogenetics：a consensus of the international myeloma working group［J］.Blood，2016，127(24)：2955-2962.
［14］Leleu X，Karlin L，Macro M，et al.Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14)：IFM 2010-02 trial results［J］.Blood，2015，25(9)：1411-1417.
［15］Dimopoulos MA，Weisel KC，Song KW，et al.Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone［J］.Haematologica，2015，100(10)：1327-1333.
［16］Avet-Loiseau H，Leleu X，Roussel M，et al.Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)［J］.J Clin Oncol，2010，28(30)：4630-4634.
［17］Bergsagel PL，Mateos MV，Gutierrez NC，et al.Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiplemyeloma［J］.Blood，2013，121：884-892.
［18］PJ Teoh，WJ Chng.p53 abnormalities and potential therapeutic targeting in multiple myeloma［J］.Bio Med Res International，2014，2014：717-919.